A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Preventing bad outcomes for teens and their offspring was the impetus behind confidential care for reproductive health. Requiring parental involvement created an obstacle to the provision of necessary care.
Transgender people planning a medical transition face decisions about family planning, fertility preservation, and how to access gender-affirming treatment.
AMA J Ethics. 2016;18(11):1119-1125. doi:
10.1001/journalofethics.2016.18.11.pfor2-1611.